De Barcelona, Barcelona, Spain. ten Departament de Medicina, Universitat Aut oma de
De Barcelona, Barcelona, Spain. 10 Departament de Medicina, Universitat Aut oma de Barcelona, Barcelona, Spain. 11Servei de Pneumologia, Hospital de Bellvitge, Feixa BRD3 Gene ID Llarga s/n, 08907L Hospitalet de Llobregat, Spain. 12IDIBELL (Institut d’InvestigaciBiom ica de Bellvitge), Gran By way of de L’Hospitalet 199, 08908 Hospitalet de Llobregat, Spain. 13Arizona Respiratory Center, Tucson, AZ, USA. 14Servei de Pneumologia, Hospital Universitari Son Espases, Carretera de Valldemosa 79, 07010 Palma de Mallorca, Spain. 15Institut de InvestigaciSanit ia de Palma (IdISPa), Carretera de Valldemossa 79, Palma, Spain. 16Thorax Institute, Hospital Cl ic, Barcelona, Spain. 17Institut d’InvestigaciBiom ica AgustPi I Sunyer (IDIBAPS), Barcelona, Spain. 18Universitat de Barcelona, Barcelona, Spain. 19FundaciInvestigaciSanit ia Illes Balears (FISIB), Palma de Mallorca, Spain. Received: 4 January 2015 Accepted: 8 January 2015 Published: 17 January 2015 References 1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary illness: existing burden and future projections. Eur Respir J. 2006;27:39712. 2. Murray CJ, L ez AD. Measuring the Global Burden of Illness. N Engl J Med. 2013;369:4487. 3. Coultas DB, Mapel D, Gagnon R, Lydick E. The health influence of undiagnosed airflow obstruction inside a national sample of United states of america adults. Am J Respir Crit Care Med. 2001;164:372. 4. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, et al. Effect of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J. 2002;20:79905. five. Soriano JB, Ancochea J, Miravitlles M, Garc -R F, BACE2 manufacturer Duran-Tauleria E, Mu z L, et al. Current trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997007. Eur Respir J. 2010;36:7585. 6. Soriano JB, Miravitlles M, Border s L, Duran-Tauleria E, Garc R F, Mart ez J, et al. Geographical variations within the prevalence of COPD in Spain: Connection to Smoking, Death Rates as well as other Figuring out Variables. Arch Bronconeumol. 2010;46:5220. 7. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the major care setting. Thorax. 2008;63:402. 8. Jordan RE, Lam KB, Cheng KK, Miller MR, Marsh JL, Ayres JG, et al. Case finding for chronic obstructive pulmonary illness: a model for optimising a targered strategy. Thorax. 2010;65:492. 9. Miravitlles M, Soriano JB, Garc -R F, Mu z L, Duran-Tauleria E, Sanchez G, et al. Prevalence of COPD in Spain: effect of undiagnosed COPD on top quality of life and each day life activities. Thorax. 2009;64:863. 10. Soriano JB, Zielinski J, Price tag D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet. 2009;374:7212. 11. Zoia MC, Corsico AG, Beccaria M, Guarnone R, Cervio G, Testi R, et al. Exacerbations as a beginning point of pro-active chronic obstructive pulmonary disease management. Respir Med. 2005;99:15685. 12. Bastin AJ, Starling L, Ahmed R, Dinham A, Hill N, Stern M, et al. High prevalence of undiagnosed and serious chronic obstructive pulmonary illness at first hospital admission with acute exacerbation. Chron Respir Dis. 2010;7:91. 13. Garcia-Aymerich J, G ez FP, AntJM. Phenotypic characterization and course of chronic obstructive pulmonary illness (COPD) within the PAC-COPD Study: design and style and solutions. Arch Bronconeumol. 2009;45:41. 14. BarberJA, Peces-Barba G, AgustAG, Izquierdo JL, MonsE, Montemayor T, et al. Clinical.
http://cathepsin-s.com
Cathepsins
